MYCN and neoplasm: In preclinical studies, inhibition of AURKA by MLN8237 (alisertib) efficiently induced N-MYC degradation, G2/M cell cycle arrest, apoptosis, and reduction in phosphorylation of the Aurora kinase substrate histone H3 in NB cells, and induced tumor regression in NB xenografts mice (Table 1) [10,175].